Protocol Ledger

NCT04337931 · Phase II · TERMINATED

A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma

Interventional Phase II clinical trial protocol NCT04337931 sponsored by Apexigen America in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-06-12 Enrollment: 45 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04337931
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)45 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04337931
Protocol FieldVerified Registry Value
NCT IdentifierNCT04337931
Consolidated Lead SponsorApexigen America
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment45 participants (ACTUAL)
Registered Start Date2019-06-12
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04337931
Hospital Research SiteLocationSite Profile
Hospital Universitari Vall d'HebronBarcelona, SpainOpen Hospital Dossier ->
Hospital Clínico San CarlosMadrid, SpainOpen Hospital Dossier ->
Hospital Universitario 12 de OctubreMadrid, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI